FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387379962> ?p ?o ?g. }

• W4387379962 abstract "PURPOSE CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was designed to determine whether high-dose methotrexate (HD-MTX) is effective at preventing CNS progression in patients at high risk of this complication. PATIENTS AND METHODS Patients age 18-80 years with aggressive B-cell lymphoma and high risk of CNS progression, treated with curative-intent anti–CD20-based chemoimmunotherapy, were included in this international, retrospective, observational study. Cause-specific hazard ratios (HRs) and cumulative risks of CNS progression were calculated according to use of HD-MTX, with time to CNS progression calculated from diagnosis for all patients (all-pts) and from completion of frontline systemic lymphoma induction therapy, for patients in complete response at completion of chemoimmunotherapy (CR-pts). RESULTS Two thousand four hundred eighteen all-pts (HD-MTX; n = 425) and 1,616 CR-pts (HD-MTX; n = 356) were included. CNS International Prognostic Index was 4-6 in 83.4% all-pts. Patients treated with HD-MTX had a lower risk of CNS progression (adjusted HR, 0.59 [95% CI, 0.38 to 0.90]; P = .014), but significance was not retained when confined to CR-pts (adjusted HR, 0.74 [95% CI, 0.42 to 1.30]; P = .29), with 5-year adjusted risk difference of 1.6% (95% CI, –1.5 to 4.4; all-pts) and 1.4% (95% CI, –1.5 to 4.1; CR-pts). Subgroups were underpowered to draw definitive conclusions regarding the efficacy of HD-MTX in individual high-risk clinical scenarios; however, there was no clear reduction in CNS progression risk with HD-MTX in any high-risk subgroup. CONCLUSION In this large study, high-risk patients receiving HD-MTX had a 7.2% 2-year risk of CNS progression, consistent with the progression risk in previously reported high-risk cohorts. Use of HD-MTX was not associated with a clinically meaningful reduction in risk of CNS progression." @default.
• W4387379962 created "2023-10-06" @default.
• W4387379962 creator A5001663845 @default.
• W4387379962 creator A5001985176 @default.
• W4387379962 creator A5005292215 @default.
• W4387379962 creator A5006324385 @default.
• W4387379962 creator A5007145110 @default.
• W4387379962 creator A5009443310 @default.
• W4387379962 creator A5010832862 @default.
• W4387379962 creator A5015983097 @default.
• W4387379962 creator A5016805730 @default.
• W4387379962 creator A5017873196 @default.
• W4387379962 creator A5019311600 @default.
• W4387379962 creator A5020447255 @default.
• W4387379962 creator A5020784348 @default.
• W4387379962 creator A5021023688 @default.
• W4387379962 creator A5021669301 @default.
• W4387379962 creator A5021775267 @default.
• W4387379962 creator A5022817237 @default.
• W4387379962 creator A5025058141 @default.
• W4387379962 creator A5025555294 @default.
• W4387379962 creator A5026641386 @default.
• W4387379962 creator A5030232385 @default.
• W4387379962 creator A5031678815 @default.
• W4387379962 creator A5037863932 @default.
• W4387379962 creator A5037878906 @default.
• W4387379962 creator A5038585259 @default.
• W4387379962 creator A5045724173 @default.
• W4387379962 creator A5045731423 @default.
• W4387379962 creator A5046515308 @default.
• W4387379962 creator A5048016549 @default.
• W4387379962 creator A5052054601 @default.
• W4387379962 creator A5053298824 @default.
• W4387379962 creator A5054469489 @default.
• W4387379962 creator A5057423528 @default.
• W4387379962 creator A5059417970 @default.
• W4387379962 creator A5060356386 @default.
• W4387379962 creator A5064305763 @default.
• W4387379962 creator A5067832483 @default.
• W4387379962 creator A5068552882 @default.
• W4387379962 creator A5068947490 @default.
• W4387379962 creator A5069125518 @default.
• W4387379962 creator A5070765060 @default.
• W4387379962 creator A5073055404 @default.
• W4387379962 creator A5073647747 @default.
• W4387379962 creator A5074827009 @default.
• W4387379962 creator A5075203908 @default.
• W4387379962 creator A5077244480 @default.
• W4387379962 creator A5079092383 @default.
• W4387379962 creator A5080184636 @default.
• W4387379962 creator A5081234421 @default.
• W4387379962 creator A5082085036 @default.
• W4387379962 creator A5082526059 @default.
• W4387379962 creator A5083724932 @default.
• W4387379962 creator A5085013906 @default.
• W4387379962 creator A5089312496 @default.
• W4387379962 date "2023-10-05" @default.
• W4387379962 modified "2023-10-16" @default.
• W4387379962 title "High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma" @default.
• W4387379962 cites W1995939575 @default.
• W4387379962 cites W2027668298 @default.
• W4387379962 cites W2028850684 @default.
• W4387379962 cites W2030776533 @default.
• W4387379962 cites W2048033270 @default.
• W4387379962 cites W2075456403 @default.
• W4387379962 cites W2077554728 @default.
• W4387379962 cites W2089242301 @default.
• W4387379962 cites W2096047333 @default.
• W4387379962 cites W2100367991 @default.
• W4387379962 cites W2112325849 @default.
• W4387379962 cites W2118192033 @default.
• W4387379962 cites W2123971450 @default.
• W4387379962 cites W2138428575 @default.
• W4387379962 cites W2142991507 @default.
• W4387379962 cites W2154868392 @default.
• W4387379962 cites W2162693374 @default.
• W4387379962 cites W2164995655 @default.
• W4387379962 cites W2171894418 @default.
• W4387379962 cites W2209130692 @default.
• W4387379962 cites W2310716991 @default.
• W4387379962 cites W2462981464 @default.
• W4387379962 cites W2470636675 @default.
• W4387379962 cites W2496211488 @default.
• W4387379962 cites W2512053872 @default.
• W4387379962 cites W2525561810 @default.
• W4387379962 cites W2531432151 @default.
• W4387379962 cites W2590821302 @default.
• W4387379962 cites W2624321043 @default.
• W4387379962 cites W2734666624 @default.
• W4387379962 cites W2794015106 @default.
• W4387379962 cites W2809101613 @default.
• W4387379962 cites W2919015634 @default.
• W4387379962 cites W2953052900 @default.
• W4387379962 cites W2966431659 @default.
• W4387379962 cites W2971529736 @default.
• W4387379962 cites W2982754619 @default.
• W4387379962 cites W2991351983 @default.
• W4387379962 cites W3026055638 @default.
• W4387379962 cites W3028381922 @default.
• W4387379962 cites W3096109923 @default.

• next